AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK
10.12.2024 09:29:00 CET | Business Wire | Press release
AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210380168/en/
Maximilien Levesque, CEO and Cofounder of AQEMIA (left) and Emmanuelle Martiano Rolland, COO and Cofounder of AQEMIA (Photo: Business Wire)
The new $38 million funding round, led by new investor Cathay Innovation, brings total funds raised since inception to over $100 million. This round, coming less than a year after the previous one, follows the successful validation of AQEMIA’s drug discovery platform through outstanding results in internal preclinical programs and pharmaceutical partnerships, particularly in oncology. The funding will support AQEMIA’s development goals, including preparations for clinical trials.
“This is a transformative moment for AQEMIA,” said Maximilien Levesque, PhD, CEO and co-founder of AQEMIA. “Less than a year after our last round, this successful fundraising and the opening of our new London office mark significant strides toward our ambition to accelerate the discovery of new medicines on a global scale. Partnering with Cathay Innovation brings international expertise, particularly in the US and Asia, reinforcing our vision and mission. With this momentum, we are poised to advance to clinical trials, bringing us closer to delivering life-changing treatments to patients in need.”
This new round is led by Cathay Innovation, followed by historical investors Wendel, Bpifrance Large Venture, Eurazeo, and Elaia.
“We have long been committed to supporting visionary entrepreneurs who harness the transformative potential of AI to reshape the healthcare industry,”supports Jacky Abitbol, partner at Cathay Innovation. “AQEMIA embodies the future of drug discovery, combining the power of AI with quantum mechanics. Fueled by Maximilien and Emmanuelle, the company’s vision is one that is fully aligned with Cathay Innovation’s DNA, as it aims to profoundly transform the molecule research and pharmaceutical industry as a whole. Our partnership goes beyond capital support; we are putting to good use our experience in scaling AI-driven companies all over the world, particularly across US and Asia, as AQEMIA accelerates its path to the clinic and expands its global impact.”
In addition to reaching the $100 million funding milestone, AQEMIA announces the opening of its London office, scheduled for January 2025 in the King’s Cross area. This expansion strengthens AQEMIA’s presence in the UK’s dynamic tech and biotech sectors. The new location will provide access to the UK’s rich talent pool, especially in life sciences and techbio, as the company continues its global recruitment efforts across all levels.
AQEMIA will also use the proceeds to continue to advance its technology platform—teaching quantum-inspired, atomic-scale physics to generative AI—to transform drug discovery, designing innovative and safe small-molecule drugs with high efficiency. By teaching theoretical physics to the generative AI, AQEMIA does not need experimental data to train on, unlocking truly innovative molecular designs, further away from existing molecules—a key challenge for genAI today. The drug discovery platform is now proven to work, as demonstrated by AQEMIA’s recent preclinical successes: (i) in their most advanced oncology programs with in vivo results, which continue to progress toward clinical trials, and (ii) through AQEMIA’s $140 million collaboration with Sanofi, announced in December 2023, which already underscored the platform's potential and strong industry recognition.
About AQEMIA
AQEMIA is a next-gen Techbio company building one of the world's fastest-growing drug discovery pipelines. Our mission is to rapidly design innovative drug candidates for critical diseases. What sets us apart is our unique use of physics and statistical mechanics algorithms to power generative AI, enabling the design of novel drug candidates without relying on experimental data. We have already achieved several drug discovery successes within our internal pipeline and through collaborations with leading pharmaceutical companies, with our most advanced programs currently undergoing in vivo optimization.
For more information, visit AQEMIA.com and our LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210380168/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom